The RLT Hub is your guide to understanding GEP-NETs, PSMA positive mCRPC and RLT
Great Britain Prescribing information for Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan) can be found here.
Northern Ireland Prescribing information for Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan) can be found here.
Prescribing information for Lutathera® (lutetium [177Lu] oxodotreotide) can be found here.
The RLT Hub was developed by Novartis, to provide information to UK health professionals interested in radioligand therapy (RLT) to support the management of their patients with neuroendocrine tumours (NET) and prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
Site features
This site provides you with the relevant information and resources to guide your knowledge and understanding of GEP-NET, PSMA positive mCRPC and RLT.
GEP, gastroenteropancreatic; mCRPC, metastatic castration-resistant prostate cancer; NET, neuroendocrine tumour; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy